Silo Pharma Regains Nasdaq Compliance After Reverse Split, Averting Delisting Threat
SILO sits 88% above its 52-week low of $3.315 on light trading volume (0.4× avg).
Summary
Silo Pharma has officially regained compliance with Nasdaq's minimum bid price requirement, confirming its stock traded above $1.00 for the necessary period. This positive development follows the 1-for-15 reverse stock split that became effective on June 2, 2026, which was implemented specifically to address the compliance issue. The news, released shortly after an 8-K filing, removes the immediate threat of delisting from the Nasdaq Capital Market, which is critical for a micro-cap company to maintain investor access and liquidity.
At the time of this announcement, SILO was trading at $6.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $3.32 to $15.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.